234 related articles for article (PubMed ID: 12874393)
1. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
3. Potassium channels, the cerebellum, and treatment for downbeat nystagmus.
Leigh RJ
Neurology; 2003 Jul; 61(2):158-9. PubMed ID: 12874391
[No Abstract] [Full Text] [Related]
4. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
Kalla R; Glasauer S; Büttner U; Brandt T; Strupp M
Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
[TBL] [Abstract][Full Text] [Related]
6. Aminopyridines for the treatment of cerebellar and ocular motor disorders.
Strupp M; Kalla R; Glasauer S; Wagner J; Hüfner K; Jahn K; Brandt T
Prog Brain Res; 2008; 171():535-41. PubMed ID: 18718350
[TBL] [Abstract][Full Text] [Related]
7. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.
Helmchen C; Sprenger A; Rambold H; Sander T; Kömpf D; Straumann D
Neurology; 2004 Aug; 63(4):752-3. PubMed ID: 15326263
[No Abstract] [Full Text] [Related]
8. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Tsunemi T; Ishikawa K; Tsukui K; Sumi T; Kitamura K; Mizusawa H
J Neurol Sci; 2010 May; 292(1-2):81-4. PubMed ID: 20181362
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacotherapy of central oculomotor disorders].
Kalla R; Spiegel R; Wagner J; Rettinger N; Jahn K; Strupp M
Nervenarzt; 2008 Dec; 79(12):1377-8, 1380-2, 1384-5. PubMed ID: 18633586
[TBL] [Abstract][Full Text] [Related]
10. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
Glasauer S; Rössert C; Strupp M
Ann N Y Acad Sci; 2011 Sep; 1233():162-7. PubMed ID: 21950989
[TBL] [Abstract][Full Text] [Related]
11. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
Kalla R; Teufel J; Feil K; Muth C; Strupp M
J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
[TBL] [Abstract][Full Text] [Related]
12. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
13. Upbeat about downbeat nystagmus.
Halmagyi GM; Leigh RJ
Neurology; 2004 Aug; 63(4):606-7. PubMed ID: 15326227
[No Abstract] [Full Text] [Related]
14. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
[No Abstract] [Full Text] [Related]
15. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus.
Glasauer S; Kalla R; Büttner U; Strupp M; Brandt T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):451-3. PubMed ID: 15716550
[TBL] [Abstract][Full Text] [Related]
16. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial.
Feil K; Claaßen J; Bardins S; Teufel J; Krafczyk S; Schneider E; Schniepp R; Jahn K; Kalla R; Strupp M
Neurology; 2013 Sep; 81(13):1152-8. PubMed ID: 23975871
[TBL] [Abstract][Full Text] [Related]
17. Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus.
Sander T; Sprenger A; Marti S; Naumann T; Straumann D; Helmchen C
J Neurol; 2011 Apr; 258(4):618-22. PubMed ID: 21057959
[TBL] [Abstract][Full Text] [Related]
18. Modelling drug modulation of nystagmus.
Glasauer S; Rössert C
Prog Brain Res; 2008; 171():527-34. PubMed ID: 18718349
[TBL] [Abstract][Full Text] [Related]
19. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Mainero C; Inghilleri M; Pantano P; Conte A; Lenzi D; Frasca V; Bozzao L; Pozzilli C
Neurology; 2004 Jun; 62(11):2044-50. PubMed ID: 15184612
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
